Subtopic Deep Dive
Orlistat as Lipase Inhibitor for Weight Management
Research Guide
What is Orlistat as Lipase Inhibitor for Weight Management?
Orlistat is a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30% to aid weight management in obese adults.
Clinical guidelines recommend orlistat alongside lifestyle changes for sustained weight loss (Yumuk et al., 2015, 3325 citations). Meta-analyses confirm orlistat achieves modest weight reduction of 2-3 kg over placebo at one year with gastrointestinal side effects (Rucker et al., 2007, 794 citations; Khera et al., 2016, 825 citations). Over 10 papers in provided lists evaluate its efficacy and safety in adults and children.
Why It Matters
Orlistat provides a non-central mechanism for weight control, reducing cardiovascular risks in obese patients when combined with diet (Padwal and Majumdar, 2007, 746 citations). Khera et al. (2016) showed orlistat yields 5% weight loss at 52 weeks versus placebo, supporting its role in guidelines (Yumuk et al., 2015). Rucker et al. (2007) meta-analysis highlights its long-term use despite side effects, influencing treatments for 1 billion obese adults worldwide.
Key Research Challenges
Gastrointestinal Side Effects
Orlistat causes steatorrhea and fecal incontinence in 15-20% of users, limiting adherence (Rucker et al., 2007). Padwal and Majumdar (2007) note these reduce long-term efficacy. Mitigation strategies remain underdeveloped.
Modest Weight Loss Magnitude
Orlistat delivers only 2.9 kg mean loss versus placebo after one year (Khera et al., 2016). Rucker et al. (2007) confirm variability across trials. Combining with behavioral interventions shows small gains (Dombrowski et al., 2014).
Long-term Safety Data Gaps
Few trials exceed 2 years, raising concerns for sustained use (Kang and Park, 2012). Guidelines like Yumuk et al. (2015) call for monitoring. Cardiovascular outcomes need clarification beyond weight loss.
Essential Papers
European Guidelines for Obesity Management in Adults
Volkan Yumuk, Constantine Tsigos, Martin Fried et al. · 2015 · Obesity Facts · 3.3K citations
Obesity is a chronic metabolic disease characterised by an increase of body fat stores. It is a gateway to ill health, and it has become one of the leading causes of disability and death, affecting...
Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline
Dennis M. Styne, Silva Arslanian, Ellen L. Connor et al. · 2017 · The Journal of Clinical Endocrinology & Metabolism · 1.2K citations
Abstract Cosponsoring Associations: The European Society of Endocrinology and the Pediatric Endocrine Society. This guideline was funded by the Endocrine Society. Objective: To formulate clinical p...
2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]
David C.W. Lau, James D. Douketis, Katherine M. Morrison et al. · 2007 · Canadian Medical Association Journal · 1.2K citations
Obesity is now reaching epidemic proportions in both developed and developing countries and is affecting not only adults but also children and adolescents. Over the last 20 years, obesity has becom...
Metabolically Healthy Obesity
Matthias Blüher · 2020 · Endocrine Reviews · 923 citations
Abstract Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities, mainly in those individuals who develop cardiovascular diseases, type 2 diabetes, osteoarthritis...
The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It
Thomas A. Wadden, Delia Smith West, Linda M. Delahanty et al. · 2006 · Obesity · 863 citations
Abstract The Look AHEAD (Action for Health in Diabetes) study is a multicenter, randomized controlled trial designed to determine whether intentional weight loss reduces cardiovascular morbidity an...
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
Rohan Khera, M. Hassan Murad, Apoorva K. Chandar et al. · 2016 · JAMA · 825 citations
Among overweight or obese adults, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, compared with placebo, were each associated with achieving at least 5% weight ...
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Diana Rucker, Raj Padwal, Stephanie K Li et al. · 2007 · BMJ · 794 citations
Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.
Reading Guide
Foundational Papers
Start with Rucker et al. (2007, 794 citations) for orlistat meta-analysis of weight loss and risks, then Padwal and Majumdar (2007, 746 citations) for mechanisms and comparisons.
Recent Advances
Study Khera et al. (2016, 825 citations) for head-to-head trials versus newer drugs; Yumuk et al. (2015, 3325 citations) for current guidelines.
Core Methods
Core techniques include RCTs with ≥5% weight loss endpoints, meta-analyses via random-effects models (Rucker et al., 2007), and GRADE for evidence quality (Yumuk et al., 2015).
How PapersFlow Helps You Research Orlistat as Lipase Inhibitor for Weight Management
Discover & Search
Research Agent uses searchPapers and citationGraph on 'orlistat lipase inhibitor weight loss' to map 3325-citation Yumuk et al. (2015) guidelines and its 50+ citers. exaSearch uncovers meta-analyses like Rucker et al. (2007); findSimilarPapers links to Khera et al. (2016) for comparative efficacy.
Analyze & Verify
Analysis Agent applies readPaperContent to extract orlistat's 30% fat absorption inhibition from Padwal and Majumdar (2007), then verifyResponse with CoVe checks claims against Rucker et al. (2007). runPythonAnalysis meta-analyzes weight loss data from Khera et al. (2016) using pandas for GRADE evidence grading on 5% threshold achievement.
Synthesize & Write
Synthesis Agent detects gaps in long-term data via contradiction flagging between short-term trials (Kang and Park, 2012) and guidelines (Yumuk et al., 2015). Writing Agent uses latexEditText, latexSyncCitations for orlistat review manuscripts, and latexCompile for publication-ready output with exportMermaid for efficacy timelines.
Use Cases
"Run meta-analysis on orlistat weight loss effect sizes from RCTs"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas forest plot of Rucker et al. 2007 data) → researcher gets CSV of 2.9kg mean difference with CI.
"Draft LaTeX review comparing orlistat to liraglutide"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Khera et al. 2016) + latexCompile → researcher gets compiled PDF manuscript.
"Find code for simulating orlistat fat absorption models"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo + githubRepoInspect → researcher gets validated simulation scripts linked to obesity models.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on orlistat, structures report with GRADE grading from Khera et al. (2016) and Rucker et al. (2007). DeepScan's 7-step chain verifies side effect claims (Padwal and Majumdar, 2007) with CoVe checkpoints. Theorizer generates hypotheses on orlistat-lifestyle synergies from Dombrowski et al. (2014).
Frequently Asked Questions
What is orlistat's primary mechanism?
Orlistat irreversibly binds pancreatic lipase, blocking 30% of dietary triglyceride hydrolysis and fat absorption (Padwal and Majumdar, 2007).
What are common methods to evaluate orlistat efficacy?
Randomized controlled trials measure ≥5% weight loss at 52 weeks versus placebo, as in Khera et al. (2016) meta-analysis of 28 studies.
What are key papers on orlistat?
Rucker et al. (2007, 794 citations) meta-analysis shows 2.9kg loss; Yumuk et al. (2015, 3325 citations) guidelines recommend it with diet.
What are open problems in orlistat research?
Long-term adherence due to GI effects and combination therapies for >10% loss remain unresolved (Kang and Park, 2012; Dombrowski et al., 2014).
Research Pharmacology and Obesity Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Orlistat as Lipase Inhibitor for Weight Management with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers